Clinical Trial Update: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluating FCN-437c plus letrozole or anastrozole (± goserelin) versus placebo in HR+/HER2- advanced breast cancer; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FCN-437c

Snippet

Sponsor: Ahon Pharmaceutical Co., Ltd. | Conditions: Advanced Breast Cancer, Female Breast Cancer | Phase 3 | Status: UNKNOWN